Table of Contents

Voglibose analysis as per IP and JP

Voglibose, an alpha-glucosidase inhibitor, is effectively used for diabetes treatment. It delays glucose absorption at the intestinal level and thereby prevents a sudden surge of glucose after a meal. It was developed in 1994 in Japan by Takeda Pharmaceuticals Industries Ltd. And shows high activity so small doses can effectively prevent side effects in the gastrointestinal tract.

Structure of Voglibose

The absence of a chromophore or conjugation in the molecule makes it difficult to detect by spectroscopic absorption in the UV – Visible region. However, post-column derivatization with a fluorescence agent provides a high sensitivity and selectivity for Voglibose in pharmaceutical formulations. This method has also been notified in Japanese Pharmacopoeia 16th edition as well as Indian Pharmacopoeia 2014.

We have introduced a post-column fluorescence derivatization system and the test conditions employed are

  • Column- SS amino column 250mmX4.6mmX5μ
  • Column temperature- [latex]25^0[/latex]C.
  • Mobile phase-37:63 mixture of phosphate buffer at ph 6.5 and acetonitrile
  • Flow rate – 0.6ml/min
  • Reaction coil temperature- [latex]100^0[/latex]C
  • Detector- Fluorescence with excitation at 350nm and excitation at 430nm
  • Fluorescence agent-Taurine 6.25 g +2.56 g Sodium periodate in 1000ml water

The method provides high precision and sensitivity of detection.

Please feel free to contact us using the contact form or call us now on +91-8588851888 and we will be happy to provide you with a proposal for testing your Voglibose products and raw material samples.

Leave a Reply

Enter the Captcha